New Delhi: The Delhi High Court has barred the export of generic kidney and liver cancer medication, Sorefenat, manufactured by Natco Pharma Ltd on the plea of German drug major Bayer Corporation.
Justice Manmohan, however, gave liberty to Natco to seek the court’s permission to export the drug as and when it gets the nod from the Drug Controlling Authority.
The court also issued notice to the Centre, customs authorities and Natco, seeking their replies on the plea of Bayer which has alleged that the generic drug is being made under compulsory licence for sale in India and thus, it cannot be exported. “Notice. Respondents 1 to 4 (centre and others) and Respondent 5 (Natco) to file their responses in six weeks... Respondents 1 to 4 are directed to ensure that no consignment from India containing
Sore fenat, covered by compulsory licence, is exported,” the court said and listed the matter for further hearing on August 11. Bayer has asked authorities to seize and confiscate the consignment manufactured by Natco Pharma Ltd under compulsory licence granted by the patent office on March 9, 2012.
